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The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly worldwide. Because of the limited
success of generic interventions, the focus of the disease study has shifted toward personalized strategies,
particularly in the early stages of the disease. Traditional Chinese medicine (TCM) is based on a systems
view combined with personalized strategies and has improved our knowledge of personalized diagnos-
tics. From a systems biology perspective, the understanding of personalized diagnostics can be improved
to yield a biochemical basis for such strategies; for example, metabolomics can be used in combination
with other system-based diagnostic methods such as ultra-weak photon emission (UPE). In this study, we
investigated the feasibility of using plasma metabolomics obtained from 44 pre-T2DM subjects to stratify
the following TCM-based subtypes: Qi-Yin deficiency, Qi-Yin deficiency with dampness, and Qi-Yin defi-
ciency with stagnation. We studied the relationship between plasma metabolomics and UPE with respect
to TCM-based subtyping in order to obtain biochemical information for further interpreting disease sub-
types. Principal component analysis of plasma metabolites revealed differences among the TCM-based
pre-T2DM subtypes. Relatively high levels of lipids (e.g., cholesterol esters and triglycerides) were impor-
tant discriminators of two of the three subtypes and may be associated with a higher risk of cardiovas-
cular disease. Plasma metabolomics data indicate that the lipid profile is an essential component
captured by UPE with respect to stratifying subtypes of T2DM. The results suggest that metabolic differ-
ences exist among different TCM-based subtypes of pre-T2DM, and profiling plasma metabolites can be
used to discriminate among these subtypes. Plasma metabolomics thus provides biochemical insights
into system-based UPE measurements.
 2019 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and
Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic, devastating, and
complex disease. T2DM is characterized by increased fasting
plasma glucose levels, impaired postprandial insulin secretion,
decreased insulin sensitivity, and impaired pancreatic beta-cellfunction [1]. In addition, patients with T2DM have increased levels
of inflammatory factors such as TNFa, IL-6, IL-8 and of reactive
active species [2,3]; altered levels of hormones, peptides, proteins,
and enzyme activity; and other metabolic perturbations [4]. Strik-
ingly, nearly all of these metabolic changes are often present years
before the patient presents with clinical symptoms leading to a
diagnosis of T2DM [5,6].
Based on epidemiology studies, an estimated 2.85  108
individuals are affected by diabetes worldwide, and this number
continues to increase [7]. Furthermore, this number is likely an
y https://clinicaltrials.gov/ct2/show/NCT00469287.
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stage due to insufficient knowledge regarding the
multi-symptom relationships at a systems level [8,9]. Receiving a
diagnosis only in a later stage of diabetes—together with the severe
complications associated with disease progression—can lead to
high costs and can reduce the efficacy of treatment [10]. For exam-
ple, long-term dysglycemia increases the risk of severe complica-
tions such as hypertension, blindness, renal failure, and
cardiovascular disease [11,12]. These complications reduce quality
of life and are a major cause of morbidity, hospitalization, and mor-
tality among patients with diabetes. Current diagnostic tests are
based primarily on a single screening tool such as the oral glucose
tolerance test or measuring fasting plasma glucose. Understanding
the symptoms that develop in an early stage of the disease and
developing indicators of disease progression would likely con-
tribute to improving both prevention and treatment strategies,
including strategies based on changes in lifestyle. Moreover, treat-
ments based on generic observations—which have led to the notion
of one drug–one target–one disease (or one-size-fits-all)—are
extremely limited, particularly in early stages of the disease. There-
fore, system-based approaches are needed in order to achieve
personalized approaches.
Integrative holistic forms of medicine such as traditional
Chinese medicine (TCM) provide descriptions of disease syn-
dromes and subtypes at a systems level, including descriptions
that can be used to diagnose early syndromes of chronic diseases.
Based on the Chinese theory for syndrome differentiation of
pre-T2DM, one important syndrome in TCM for pre-diabetes is
‘‘Qi-Yin deficiency” (QYD). Other pathological factors such as
dampness or stagnation interact with the QYD, leading the devel-
opment of the disease in two different directions or toward two
different statuses. From a pharmacological perspective, QYD can
be used to reflect hypermetabolism-induced mild inflammatory
status and chronic fatigue syndrome. Both dampness and stagna-
tion are closely related to an unhealthy lifestyle and poor diet:
Dampness can lead to complications such as metabolic syndrome,
hypertension, and anginosis, while stagnation may be associated
with pressure and tension, thereby leading to emotional prob-
lems, impaired blood circulation, and diabetic peripheral neu-
ropathy. Such descriptions can be used as a guide or reference
in order to achieve personalized medicine. In this respect, TCM
has provided descriptions of pre-T2DM syndromes, indicating its
potential for assisting in the development of personalized medi-
cine [13,14]. To build a bridge between TCM and western medi-
cine, evidence-based scientific data is needed at the biochemical
level. Modern systems biology research—including metabolo-
mics—is a promising approach for exploring the biochemistry
underlying TCM subtyping.
Metabolic disorders are often present for years before the
appearance of clinical disease, and metabolomics is a widely used
technique for predicting and diagnosing disease [15]. Metabolo-
mics provides a comprehensive profile of small molecular metabo-
lites in biological systems and can be used as a readout of an
organism’s physiological status [16]. In principle, this approach is
well suited to studying complex TCM-based diagnostics. Metabolo-
mics is generally performed on fluids such as blood, urine, and
cerebrospinal fluid. Urine is commonly used for metabolomics, as
it easily obtained, contains information regarding the excretion
of products, and can reflect how metabolic processes change dur-
ing the disease process. Several studies have used urine metabolo-
mics to explore TCM-based diagnostics and T2DM syndrome
subtypes [17,18]. Like urine, blood contains information regarding
the body’s regulatory status and dynamics. Thus, performing meta-
bolomics on different fluids can provide complementary informa-
tion, thereby improving our understanding of T2DM. An
explorative study at the Netherlands Organization for AppliedScientific Researchy (TNO; Zeist, the Netherlands) was designed in
which 44 pre-T2DM subjects received a diagnosis by a panel of three
TCM-trained physicians [17], and we explored these TCM-based sub-
types using plasma metabolomics.
Recently, a sensitive, non-invasive technique has been proposed
for supporting TCM-based diagnostics [19]. This technique, called
ultra-weak photon emission (UPE), is used to measure sponta-
neous photon emissions from the skin’s surface [20]. Because
UPE reflects the body’s physiological and pathological status, it
represents a promising tool for use in clinical diagnostics at a sys-
tems level [21–23]. The underlying biochemistry of UPE is related
to metabolism and is correlated with reactive oxygen species in
oxidative metabolic processes [24–27]. Although the use of UPE
properties for characterizing TCM-based diagnostics has been sum-
marized previously [19,20,28], further understanding of the molec-
ular basis of UPE is needed. Metabolomics can be combined with
TCM-based diagnostics to investigate the biological meaning of
UPE and to explore the added value of each technology. It is impor-
tant to note that UPE was used previously to subtype the same
cohort of 44 subjects with pre-T2DM [28], thereby enabling us to
study the correlation between UPE and plasma metabolomics.2. Materials and methods
2.1. Inclusion criteria for the selection of pre-T2DM subjects and the
diagnosis of syndrome subtypes based on TCM
The recruitment of subjects and the diagnosis of pre-T2DM sub-
types by TCM-trained physicians have been described previously
[17]. In brief, clinical parameters were obtained from 44 male
Dutch subjects who met the following inclusion criteria: 30–
70 years of age, body mass index of 26–35 kgm2, and a fasting
glucose level of 6.1–6.9 mmolL1. No other clinical abnormalities
or evidence of diabetic complications were detected. The subjects
were then diagnosed separately in a blinded study by three TCM-
certified physicians with at least five years of training in TCM
and at least ten years of clinical experience. Three categories were
based on 26 TCM-based diagnostic terms, and 85% consensus was
reached among the three TCM physicians with respect to diagnos-
ing the subjects. These three categories are defined as follows: QYD
(n = 15 subjects), Qi-Yin deficiency with dampness (QYD_Damp,
n = 20 subjects), and Qi-Yin deficiency with stagnation (QYD_Stag,
n = 9 subjects). Blood samples were collected after overnight fast-
ing and used for the metabolomics study. In addition, UPE was
measured from the palmar and dorsal surfaces of both hands.
2.2. Ethics statement
This explorative study was designed and conducted by TNO and
was approved by the Medical Ethics Committee of Tilburg
(METOPP).
2.3. Data acquisition
2.3.1. Plasma metabolomics profiling
Metabolic profiles were measured by TNO. Heparinized blood
samples were collected, and plasma was obtained by centrifuga-
tion (4000 rmin1 at 4 C for 15 min). The plasma samples were
aliquoted and stored at 20 C prior to metabolite extraction and
mass spectrometry.
Using a gas chromatography–mass spectrometry (GC–MS) plat-
form, a large variety of metabolic classes were measured, including
amine metabolites, organic acids, sugars, and lysophosphatidic
y http://www.metaboanalyst.ca/.
 http://www.cytoscape.org.
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the GC–MS analysis protocol have been published previously
[29]. In brief, 100 lL aliquots of plasma were spiked with a mixture
of internal standards (ISTDs) and deproteinized with methanol.
After centrifugation, the supernatant was transferred to a new
sample vial for evaporation and two-step derivatization. The
derivatized extracts were then analyzed using an Agilent 6890
gas chromatograph (Agilent Technologies, Inc., USA) on a J&W
BD-5 ms capillary column (30 m  250 mm i.d., 0.25 mm film thick-
ness; Agilent Technologies, Inc., USA) coupled to an Agilent 5973
mass selective detector (Agilent Technologies, Inc., USA); helium
was used as the carrier gas at a flow rate of 1.7 mLmin1 for
temperature-programmed gradient chromatographic separation.
The raw data were preprocessed and exported using ChemStation
G1701CA software (version D.01.02; Agilent Technologies, Inc.,
USA), providing response ratios to the appropriate ISTD for each
metabolite; these ratios were used for further statistical analysis.
For liquid chromatography–tandem mass spectrometry (LC–
MS) lipid measurements, seven classes of lipids, including polar
lipids (e.g., phosphatidylcholine, phosphoethanolamine, lyso-
phosphatidylcholine, lyso-phosphoethanolamine, and sphin-
gomyelin) and non-polar lipids (e.g., cholesterol esters (ChEs) and
triglycerides (TGs)), were investigated using targeted analysis, as
reported previously by Van Wietmarschen et al. [30] and Draisma
et al. [31]. In brief, 10 mL aliquots of plasma were deproteinized by
the addition of isopropanol containing a mixture of ISTDs. The
lipids were separated and analyzed using a TSQ Quantum Discov-
ery Triple Quad mass spectrometer coupled to a Surveyor MS HPLC
System (Ultimate 3000, TSQ Endura; Thermo Fisher Scientific, Inc.,
USA) on an Alltech Prosphere C4 300 Å column (150 mm  3.2 mm,
particle size of 5 lm; Alltech Associates, Inc., USA) in combination
with a Symmetry 300 C4 guard column (2.1 mm  10 mm, particle
size of 3.5 lm; Waters, USA) in positive ionization mode. The peak
areas of the target lipids were integrated, and raw data were
exported using LCQUAN software (version 2; Thermo Fisher Scien-
tific, Inc., USA), yielding response ratios to the appropriate ISTD for
each metabolite; these ratios were used for further statistical
analysis.
During the GC–MS and LC–MS experiments, quality control
(QC) samples were prepared by pooling equal amounts of plasma
from each sample, and then dividing the pooled samples into ali-
quots; these QC samples were used to check the performance of
the LC–MS platform and to identify temporal trends in the
acquired data. The relative standard deviation (RSD) of each target
peak in the QC samples was used to confirm the quality of the data
acquired from each analytical platform.
2.3.2. UPE measurements
UPE signals were measured from the same cohort of 44 sub-
jects. A photomultiplier system (provided by Meluna Research
BV, the Netherlands) with two detecting heads located at the top
of a dark chamber was used to measure UPE. Each detecting head
contains a 9235QA photomultiplier tube within a spectral sensitiv-
ity range of 160–630 nm (Electron Tubes Enterprises Ltd., UK) and
an electronically controlled shutter. The dark chamber was main-
tained at (20 ± 1.0) C. The settings used to measure UPE have been
described previously [32,33]. All measurements were controlled
automatically via computer-driven software. UPE signals were
measured at the following four hand surfaces: left dorsal (LD), right
dorsal (RD), left palm (LP), and right palm (RP).
2.4. Data preprocessing and statistical analysis
2.4.1. Metabolomics data processing and analysis
Before performing statistical analysis on the metabolomics data,
the log-transformed dataset was processed using various scalingoptions (i.e., autoscaling, range scaling, and Pareto scaling) using
the online software package MetaboAnalyst 3.0y [34]. The Pareto-
scaling approach (mean-centered and scaling by the square root of
the standard deviation of each variable) was chosen because it pro-
vided the best grouping performance, consistently explaining the
largest variabilities when considering the same number of principal
components (both two-dimensional (2D) and three-dimensional
(3D)) [35–37]. Preliminary selection of variables prior to multivari-
ate analysis has been applied in order to: ① limit the dataset of vari-
ables in order to reliably separate the sample groups, ② remove
irrelevant and/or confounding variables, and ③ decide which vari-
ables to retain for the further multivariate analysis. However, this
selection is not with the aim to identify potential biomarkers, which
have been applied in metabolic profiling studies [38] using p-values
obtained from a one-way analysis of variance (ANOVA) (p < 0.1) in
GC–MS and LC–MS. Multiple comparisons, including principal com-
ponent analysis (PCA) and OPLS-DA, were conducted using
MetaboAnalyst 3.0, which provides standard validation information
including cross-validation and a permutation test to prevent over-
fit of the models to the data [34].
2.4.2. Acquisition of UPE data and derived parameters
From a 50 ms bin, the following ten UPE properties were calcu-
lated from all four hand surfaces: strength, FF0, FF1, FF2, alpha,
gamma, theta, phi, SSI, and SSR [32,33,39]. Thus, a total of 40
UPE parameters were obtained from each subject.
2.4.3. Correlation analysis
The statistics software package R (version 3.0.3) was used to
calculate Spearman’s rank correlation coefficient in order to exam-
ine the relationship between the metabolites and UPE parameters.
A graphical overview of the correlation networks was created using
CytoScape version 3.3.0 with the MetScape plugin [40,41]. Positive
and negative correlations are indicated by positive and negative val-
ues of r, respectively.3. Results and discussion
3.1. Subtyping based on plasma metabolomics
TCM-based diagnostics use important information on personal-
ized phenotypes (so called ‘‘syndrome subtypes”) at a holistic level.
The identification of these syndrome subtypes is the most impor-
tant concept guiding personalized interventions in TCM. Therefore,
exploring TCM-based diagnostics may provide fresh insight into
personalized healthcare and management strategies. However,
TCM-based diagnostics are descriptive, phenomenological con-
cepts that are based on several standard diagnostic steps, including
inspection, listening and smelling, inquiry and questioning, and
palpation. The outcomes from these steps are combined to create
an individual profile, which is used to establish a diagnosis. There-
fore, objective, evidence-based data are needed in order to support
TCM-based diagnostics. In this study, 26 TCM-based diagnostic
terms were determined in order to classify different syndrome
subtypes in 44 pre-diabetic subjects [17]. From this exploratory
study, plasma samples were used to obtain evidence-based infor-
mation that was used to help subtype the pre-T2DM subjects.
We used two validated metabolomics methods based on GC–
MS and LC–MS. GC–MS yielded 147 untargeted metabolites, and
LC–MS yielded 110 targeted metabolites; all of these metabolites
were included in the total metabolomics profile. The metabolites
detected by GC–MS included various metabolic classes, but
Fig. 1. 3D PCA score plot of the log-transformed and Pareto-scaled data for the
three pre-T2DM subtypes. PC: principal component.
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fatty acids such as LPA and LPA-derived metabolites. The
metabolites detected by LC–MS could be classified into seven
classes of lipids including polar lipids (e.g., phosphatidylcholine,
phosphoethanolamine, lyso-phosphatidylcholine, lyso-phosphoet-
hanolamine, and sphingomyelin) and non-polar lipids (e.g., ChEs
and TGs). Given the relatively small number of subjects (44) com-
pared to the large number of total variables (257), a first step of
selecting variables was required before proceeding with a multi-
variate analysis. This step allowed us to optimize the variable/
object ratio for discriminant type approaches and allowed us to
remove potential irrelevant and/or confounding variables [38]. A
total of 32 preliminary variables were selected based on an ANOVA
(p < 0.1); these variables included 14 plasma metabolites identified
by GC–MS and 17 plasma lipids identified by LC-MS. These vari-
ables were then used for subsequent multivariate analyses, includ-
ing PCA, partial least squares discriminant analysis (PLSDA), and
OPLS-DA (see Table S1 and Fig. S1).
The first step in our analysis focused on investigating whether
plasma metabolomics could be used to discriminate between the
three TCM-based syndrome subtypes of pre-T2DM (i.e., QYD vs.
QYD_Damp, QYD vs. QYD_Stag, and QYD_Damp vs. QYD_Stag). A
3D PCA plot was used to visualize the natural distribution of the
three groups in 3D space [38,42]. The first three principal compo-
nents analyzed described 66.5% of the total variance in the plasma
metabolome (Fig. 1). We found no large distance between the three
subtypes reflected by PCA, which is not surprising given that their
TCM-based diagnostic patterns are all linked (interrelated) and
that TCM-based syndromes subtypes are not independent but
show dynamic changes toward different directions [13,14]. How-
ever, we did observe a tendency toward clusters within the sub-
types, with minor overlap in the PCA analysis.
Next, we used supervised models, including linear discriminant
analysis (LDA), PLSDA, and OPLS-DA, in order to identify relevant
plasma metabolites (Fig. S2). The OPLS-DA model provided the
highest R2 and Q2 values and was therefore used to identify the
most relevant variables based on score plots [43,44]. Furthermore,
permutation tests with 1000 iterations (p < 0.05) showed a good
performance of the model. Fig. 2 shows the OPLS-DA score plots
for the first two principal components between each pair of sub-
types (see also Fig. S3).
Table 1 summarizes the relevant metabolites (defined as the
combination of covariance |p[1]| > 0.7 and correlation coefficient
|p(corr)| > 0.3 [44]) for each pair of groups, together with their con-
tribution toward each pair of subtypes (QYD vs. QYD_Damp, QYD
vs. QYD_Stag, and QYD_Stag vs. QYD_Damp). As shown in Table 1,
14 of the 18 metabolites that contributed to the differentiationFig. 2. OPLS-DA score plots of the first two principal components for each pair of subtyp
QYD_Stag: R2Y = 0.93, Q2 = 0.62, permutation p < 0.001; (c) QYD_Damp vs. QYD_Stag: R2between QYD and QYD_Damp are long-chain non-polar lipids
(ten TGs and four ChEs); these metabolites were present in higher
levels in the QYD_Damp group than in the QYD group. The TGs and
ChEs (ten TGs and four ChEs) were also present in higher levels in
the QYD_Stag group than in the QYD group, although two of those
(C58_10_TG and C22_5_ChE) were not appeared in the comparison
between QYD and QYD_Damp. Thus, we conclude that an increase
in long-chain non-polar lipids is associated with the QYD_Damp
and QYD_Stag groups.
The physiological mechanisms that underlie the early phases of
T2DM have been linked to lifestyle issues such as the consumption
of a diet high in fat and calories [45–48]; in this aspect, the early
phases of T2DM are similar to chronic fatigue syndrome and/or
mild inflammatory status [17]. TGs are the precursors of phospho-
lipids, which are the building blocks of cell membranes and play an
important role in energy homeostasis. ChEs are a stored form of
cholesterol that is normally exported as a high-density lipoprotein
(HDL) and returned to the liver. High levels of cholesterol and TGses. (a) QYD vs. QYD_Damp: R2Y = 0.61, Q2 = 0.36, permutation p = 0.001; (b) QYD vs.
Y = 0.69, Q2 = 0.48, permutation p < 0.001.
Table 1
List of relevant metabolites identified by OPLS-DA.
Pair of subtypes Metabolite Change
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The sequence of the metabolites indicates their importance for the contribution to
the group separations.
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*: structural unidentified metabolites in GC–MS untargeted measurement.
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associated with fat accumulation, atherosclerosis, and cardiovascu-
lar disease [49,50]. Therefore, patients in the pre-T2DM subgroups,
QYD_Damp and QYD_Stag, may have an increased risk of develop-
ing atherosclerosis and/or cardiovascular disease in a later disease
stage.
Although TGs and ChEs were increased in both the QYD_Damp
and QYD_Stag groups relative to the QYD group, these two groups
had several metabolic differences (Table 1). The relatively lower
levels of amine metabolites in the QYD_Stag group (and/or the
relatively higher levels in the QYD_Damp group) may suggest that
the difference between the QYD_Stag and QYD_Damp subtypes is
based primarily on differences in the tricarboxylic acid (TCA) cycle
and/or muscle catabolism processes [51]. In summary, 23 metabo-
lites contribute to the stratification of pre-T2DM subtypes. Thus,
different pre-T2DM subtypes may be discriminated based on dif-
ferences in plasma metabolomics, including plasma lipids and
amine metabolites.
Previously, Wei et al. [17] reported that urine metabolomics can
be used to reflect changes in carbohydrate metabolism and renal
function in patients with QYD_Stag syndrome; specifically, two
of the three TCM-based subtypes could be stratified (between
QYD and QYD_Stag or between QYD_Damp and QYD_Stag). In
contrast, plasma metabolomics provides stratification among thethree subgroups; to be specific, QYD and QYD_Damp could be
stratified successfully using plasma metabolomics, probably due
to the use of a lipidomics platform, which measures a class of com-
pounds that cannot be measured using urine metabolomics. This
finding suggests that measuring lipid metabolomics is important
for accurately subtyping pre-T2DM. In the previous study [17],
urine metabolomics was shown to provide additional biomarkers
to understand the differences between QYD_Damp and QYD_Stag;
this finding indicates that performing various metabolomics plat-
forms using different body fluids may provide more comprehen-
sive information to study TCM-based diagnostics.
3.2. Correlation between metabolomics and UPE
Analytical methods can only be performed using currently
available analytical platforms, which may not necessarily cover
the entire profiling. Therefore, complementary tools are still
needed in order to further characterize TCM-based diagnostics at
an integrated, dynamic systems level. Measuring UPE may
approximate the organizational level of TCM-based diagnostics,
since UPE has been proposed as a non-invasive indicator of the
integrated states in living organisms [19]. UPE measurement has
matured to be rapid and highly sensitive, and there is some evi-
dence that measuring UPE from human hands is sufficient to
reflect body states [19]. As a promising tool, UPE has been sug-
gested for use in clinical research [21]. Therefore, we measured
UPE in our cohort of subjects with pre-T2DM. Stratification of the
three TCM-based syndrome subtypes using 16 UPE parameters
has been studied previously [28]. However, the molecular interpre-
tation of UPE parameters requires further study. One available
strategy is to link metabolomics to UPE [23,52]. Given that both
plasma metabolomics and UPE can stratify subjects into pre-
T2DM subgroups, plasma metabolomics data may be used to
obtain biochemical insight into UPE [53–55]. To explore the rela-
tionship between these two approaches, we used Spearman’s rank
correlation coefficient to establish a correlation-based metabolite-
to-UPE network. Such a correlation network may provide addi-
tional information that may further stratify disease subtypes and
provide a biochemical interpretation of UPE parameters.
We generated correlation networks between the 23 metabolites
and 16 UPE parameters that contributed to the stratification of
subtypes in order to visualize the most relevant correlations
related to the three subtypes (Fig. 3). These networks revealed
clearly distinct distributions of UPE-to-metabolite correlations
between the three subtypes. Specifically, the QYD_Damp subtype
contained relatively few correlations, whereas the QYD_Stag sub-
types contained relatively more positive and negative correlations
compared with the QYD group.
First, in TCM, these three subtypes share a common, basic,
cross-biological background syndrome—QYD—and the additional
pathological factor (dampness or stagnation) reflects different
symptoms that should be treated using different interventions
[28]. Therefore, the different distributions of UPE-to-metabolite
correlations in QYD_Damp and QYD_Stag may indicate the differ-
ent dynamic changes in different directions in comparison with
QYD.
Second, the principle source of UPE is closely related to the
generation of reactive oxygen species (ROS) during metabolic
processes [19]. The cellular damage inflicted by ROS has been
associated with many diseases; in particular, the overproduction
of ROS will result in pathogenesis of diabetes mellitus [4]. A major
source of ROS is a family of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidases. Increased lipid-derived signaling
molecules may lead to activation of NADPH oxidase, hence
resulting in cellular oxidative damage [56]. We found that lipid
metabolites were present in higher levels in the QYD_Damp group
Fig. 3. Correlation networks between metabolic variables and UPE parameters for
the indicated pre-T2DM subtypes: (a) QYD; (b): QYD_Damp; and (c) QYD_stag. Only
the correlations between metabolites and UPE parameters with |r| > 0.3 are plotted.
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metabolomics. This findingmight provide a potential interpretation
of the different UPE-to-metabolite correlation distributions of the
QYD_Damp group and QYD_Stag group compared with the QYD
group. On the other hand, we found that the major differences in
plasma metabolites were in the amine metabolites between the
QYD_Damp group and QYD_Stag group; furthermore, the previousurine metabolites showed us that the QYD_Stag group had higher
sugars levels than the QYD_Damp group [17]. Reducing sugars
can react with a free amino group to produce a Schiff base, which
can further lead to the accumulation of the Amadori products. In
contrast, the Amadori glycation product tends to accumulate in
proteins, leading to advanced glycation that results in the genera-
tion of ROS [4]. This information may help us to understand why
the UPE-to-metabolite correlation is distributed differently in the
QYD_Damp group and QYD_Stag group.
Third, the 16 UPE parameters indicate not only the photon
intensity (Str) but also the photon-counting statistic properties
(FF, SSI, alpha, etc.) [32,33]. The photon-counting statistic proper-
ties describe the photon emission distribution within a certain
measurement time. That means that these properties are based
on the timing of photon signals. This is crucial in order to under-
stand the link between UPE and metabolic procedures from a sys-
tematic view. Although both QYD_Damp and QYD_Stag show
increased levels of long-chain non-polar lipids compared with
QYD, Fig. 3 reveals that the QYD_Stag group shows many strong
correlations between these lipids and the UPE parameters, whereas
the QYD_Damp group does not. This finding demonstrates that the
UPE parameters are not only dependent on the quantity of ROS-
producing molecules. The differences between the QYD_Damp
and QYD_Stag groups lie in their amine metabolites and sugar
levels. Both sugar and amine metabolisms belong to the tightly
coupled metabolic network system in cells. The deficiency of a sin-
gle metabolism may influence the whole metabolic network and
further change the UPE in both the intensity (quantity of ROS)
and timing of UPE emission (when the ROS are produced).
In brief, although clear links are visible between UPE parame-
ters and specific classes of metabolites (e.g., TGs and ChEs), the cor-
relations differ among the subtypes. The differences between the
three networks provide a clear distinction between the subgroups
and might serve as an additional diagnostic tool. However, further
clinical trials must be performed using larger pre-diabetic and dia-
betic subject cohorts in order to investigate detailed biological
mechanisms for both UPE and TCM-based diagnostics. This will
not only provide new insight into biochemical interpretation for
UPE to support its clinical application, but also provide more
evidence-based data for TCM-based diagnostics.4. Conclusions and perspectives
In this paper, we report that plasma metabolomics can be used
to stratify the three TCM-based subtypes of early-stage type 2 dia-
betes, and provide better stratification than urine metabolomics.
To be specific, increased levels of plasma lipids such as TGs and
ChEs may indicate a relatively higher risk of developing cardiovas-
cular disease among patients with specific subtypes. In addition,
we used UPE as a non-invasive method for subtyping pre-T2DM;
the UPE parameters were correlated with specific plasma metabo-
lites—primarily lipid metabolites—and these correlations differed
among the three subtypes. Thus, combining UPE with plasma
metabolomics provides additional insight into the diagnosis of dis-
ease and the underlying biochemistry of UPE from a systems biol-
ogy perspective.
The ability to identify the pre-T2DM syndrome subtype based
on TCM is essential for achieving a personalized treatment plan,
which will significantly improve patient care. These results provide
a window of opportunity for combining metabolomics with UPE in
order to achieve personalized medicine and improve the early
diagnosis of disease. Nevertheless, metabolomics platforms do
not necessarily cover the entire metabolome, and choices must
be made based on the metabolomics platforms that are currently
available. Given the difficulties associated with obtaining compre-
922 M. He et al. / Engineering 5 (2019) 916–923hensive information regarding the dynamic changes reflected by
measuring metabolomics, linking metabolomics to UPE under the
guidance of TCM-based diagnostics is particularly attractive for
promoting the early diagnosis of T2DM. Additional research is
needed in order to expand the correlation networks between
metabolites and UPE parameters. In addition, current approaches
for stratifying T2DM are based on varied criteria, which must be
consistent for further clinical diagnosis. Therefore, additional
research is needed in order to understand TCM-based concepts
such as disease syndromes and subtypes.
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